Hydrocephalus Market Report 2025

The hydrocephalus market size has grown steadily in recent years. It will grow from $3.54 billion in 2024 to $3.69 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to neurological disorders awareness, pediatric healthcare advances, increased incidence of traumatic brain injuries, improved access to healthcare, research and development initiatives.

The hydrocephalus market size is expected to see strong growth in the next few years. It will grow to $4.66 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to neuroendoscopy advancements, growing geriatric population, regulatory support for medical devices, rise in traumatic brain injuries, global health initiatives. Major trends in the forecast period include increased focus on pediatric neurology, technological innovations in shunt systems, advancements in medical technology, advancements in surgical techniques, innovation in shunt technologies.

The rising prevalence of hydrocephalus is a significant factor driving the growth of the hydrocephalus market. Hydrocephalus is a medical condition characterized by the accumulation of cerebrospinal fluid (CSF) in the brain's cavities, leading to various cognitive abnormalities. The increasing incidence of hydrocephalus is boosting the demand for treatment devices to care for patients. For example, in August 2022, the Hydrocephalus Association, a US-based private non-profit organization, reported that hydrocephalus affects approximately 1 million Americans, with 1 in 770 infants diagnosed with the condition. Additionally, around 700,000 seniors in the U.S. are living with normal pressure hydrocephalus (NPH). Thus, the growing prevalence of hydrocephalus is anticipated to drive the expansion of the hydrocephalus market.

The swift growth of healthcare infrastructure is anticipated to drive the hydrocephalus market in the coming years. Healthcare infrastructure encompasses the system of buildings, organizations, and resources dedicated to promoting, restoring, and maintaining health. It consists of various components that collaborate to provide healthcare services to individuals and communities. A well-developed healthcare infrastructure is essential for delivering comprehensive and specialized treatment to patients with hydrocephalus. It facilitates prompt diagnosis, appropriate therapy, and ongoing care, all of which contribute to better outcomes for individuals affected by this condition. For example, in March 2022, the Department of Health and Aged Care, an Australian government agency responsible for funding, promoting, regulating, and conducting health research, announced that the newly elected Coalition would invest an unprecedented $132 billion in healthcare infrastructure for 2022-23, increasing to $140 billion by 2025-26, totaling $537 billion in commitments over the next four years. Therefore, the rapid expansion of healthcare infrastructure is propelling the hydrocephalus market.

Leading companies in the hydrocephalus market are innovating advanced products, including endovascularly implantable cerebrospinal fluid (CSF) shunts, to enhance the management of hydrocephalus by offering minimally invasive solutions for regulating CSF flow and alleviating intracranial pressure. An endovascularly implantable CSF shunt is a type of shunt system positioned within blood vessels (endovascularly) to address hydrocephalus, a condition marked by excessive CSF accumulation in the brain. For example, in August 2024, CereVasc Inc., a clinical-stage medical device company based in the US, received approval from the Food and Drug Administration (FDA) for its eShunt System. This medical device is designed for treating Normal Pressure Hydrocephalus (NPH) and includes an endovascularly implantable CSF shunt that aims to eliminate the need for invasive surgery and general anesthesia. The implantation of the eShunt will be conducted under local anesthesia using a minimally invasive femoral venous approach in an angiography suite, which is a specialized medical facility.

Key players in the hydrocephalus market are concentrating on developing products like non-invasive flushing to enhance patient outcomes and reduce the need for surgical intervention. Non-invasive flushing refers to a technique used in shunt systems to clear blockages without surgical procedures. For instance, in July 2023, Anuncia Medical Inc., a US-based medical equipment manufacturer, launched the ReFlow Mini Flusher, which received FDA approval. The ReFlow Mini Flusher is designed to treat hydrocephalus, characterized by the accumulation of CSF in the brain. This device allows for non-invasive flushing of CSF back into the ventricular catheter through a soft dome that can be depressed beneath the patient's scalp. This feature enables trained caregivers or clinical staff to easily perform flushing procedures in either a clinical setting or at home. The ReFlow Mini Flusher is compatible with any shunt system brand, making it versatile for various clinical practices.

In January 2022, ICU Medical Inc., a US-based manufacturing company of valves, acquired Smiths Medical, Inc. for an undisclosed amount. Through this acquisition, Smiths Medical complements ICU Medical's existing company and creates a scalable US-based worldwide rival, strengthening the stability of the medical supply chain and having the potential to grow as clinical care models develop. Smiths Medical, Inc. is a US-based valve and diagnostics manufacturing company.

Major companies operating in the hydrocephalus market include Johnson & Johnson Corporation, Thermo Fisher Scientific, Medtronic plc, MIZUHO Co. Ltd., B. Braun Melsungen AG, Helios Hospital, Agilent Technologies Inc., Texas Children's Hospital, Boston Children’s Hospital, Karl Storz Se And Co. Kg, Integra LifeSciences Corporation, Children's National Hospital, Natus Medical Incorporated, Aesculap Inc., HLL Lifecare Limited, Sophysa SA, Anadolu Medical Center, Christoph Miethke GmbH & Co. KG, Alcyone Therapeutics Inc., Moller Medical GmbH, Spiegelberg GmbH & Co. KG, G. SURGIWEAR LTD., Tokibo Co. Ltd., HpBio Proteses Inc., Desu Medical, Dispomedica GmbH, Kaneka Medix Corporation, Delta Surgical Limited.

North America was the largest region in the hydrocephalus market in 2024. The regions covered in the hydrocephalus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hydrocephalus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hydrocephalus is a medical condition where cerebrospinal fluid accumulates in brain cavities, leading to various cognitive abnormalities, deviating from its normal passage through the brain and spinal column spaces.

The primary types of hydrocephalus include congenital hydrocephalus, acquired hydrocephalus, normal-pressure hydrocephalus, and ex-vacuo hydrocephalus. Congenital hydrocephalus results from birth abnormalities or brain malformations, leading to excessive cerebrospinal fluid (CSF) accumulation. Hydrocephalus can be pediatric or adult, detectable through MRI, CT scans, head ultrasound, and others, with end-users including hospitals, diagnostic centers, academic institutions, and research organizations.

The hydrocephalus market research report is one of a series of new reports that provides hydrocephalus market statistics, including hydrocephalus industry global market size, regional shares, competitors with a hydrocephalus market share, detailed hydrocephalus market segments, market trends and opportunities, and any further data you may need to thrive in the hydrocephalus industry. This hydrocephalus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hydrocephalus market consists of sales of shunts, valves, and accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.